Pharmaceuticals

FDA Approves Incyte and Syndax Pharmaceuticals’ Nictimvo for Chronic Graft-Versus-Host Disease

bexib
By bexib 0 Min Read

Niktimvo’s approval was based on positive data from the AGAVE-201 trial, which demonstrated a 75% response rate in patients with chronic graft-versus-host disease.

You Might Also Like

Pharma Pulse 5/23/24: GoodRx offers discounts on fertility treatments and more, medical services immigrant children need most

Sun Life Expands Coverage Connections

European Association for Medical Education AMEE 2024 Conference

FDA Approves Merck’s Capvaxive to Prevent Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults 18 Years and Older

Eli Lilly’s Chief Financial Officer Steps Down

Share This Article
Previous Article FDA approves AstraZeneca’s Imfinzi in combination with chemotherapy for resectable early-stage non-small cell lung cancer
Next Article Gen AI reduces Discover agent response times by 70%
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

China’s seapower expands as US shipyards decline
Manufacturing
Print advertising is an e-commerce opportunity
Retail & E-commerce
Top 6 banking trends to grow across Asia in 2025
Fintech
The Difference Between Direct Carrier Appointments and Producer Sub-Codes
Insurance